Our publications

Scientific excellence is central to everything we do. We believe breakthrough medicines begin with breakthrough science. Explore our publications to see the research and evidence driving our innovative approach to preventing and treating respiratory viral infections.

Our scientific approach

The following video explains the comprehensive body of evidence reported in our most recent publication in Science Translational Medicine (Feb 2026) related to our approach to use broadly protective antibodies to defend against influenza.

Our scientific publications

February 4, 2026

Phase 1 and preclinical studies reveal safety, pharmacokinetics, and efficacy of intranasal delivery of the influenza antibody CR9114

Published in Science Translational Medicine

In collaboration between Leyden Labs and Harvard University, University of Kent and University of Greenwich, University of Sheffield, and Beth Israel Deaconess Medical Center

December 7, 2025

Preventing SARS-CoV-2 superspreading events with antiviral intranasal sprays

Published in Journal of Theoretical Biology

In collaboration between Leyden Labs and Imperial College London, University of Sussex, and Harvard University

June 13, 2025

Data dashboard to support meta-analyses on influenza vaccine effectiveness across regions, influenza seasons and outcomes

Preprint published on medRxiv

May 6, 2025

A Non-Lipid Nanoparticle Platform for Targeted RNA Therapeutic Delivery

Published in Respiratory Drug Delivery

May 6, 2025

Modelling the Impact of Mucoadhesive Formulations on Intranasal Delivery of RIG-101, a Stem-Loop Ribonucleic Acid Therapeutic

Published in Respiratory Drug Delivery

April 08, 2025

Intranasal administration of a panreactive influenza antibody reveals Fc-independent mode of protection

Published in Scientific Reports

In collaboration between Leyden Labs and Harvard University,  Wageningen University & Research,  University of Kent and University of Greenwich, The Ragon Institute, and Maastricht University

February 15, 2024

A pan-influenza monoclonal antibody neutralizes H5 strains and prophylactically protects through intranasal administration

Published in Scientific Reports

In collaboration between Leyden Labs and Harvard University,  University of Manchester, University of Sussex, and  University of Kent and University of Greenwich

February 04, 2023

SARS‑CoV‑2 elicits non‑sterilizing immunity and evades vaccine‑induced immunity: implications for future vaccination strategies

Published in European Journal of Epidemiology

In collaboration between Leyden Labs and Harvard University, University of Manchester, Imperial College London, and the Ragon Institute

January 5, 2023

A rapid RIG-I signaling relay mediates efficient antiviral response

Published in Molecular Cell

November 3, 2022

The RIG-I receptor adopts two different conformations for distinguishing host from viral RNA ligands

Published in Molecular Cell

November 02, 2022

The influenza hemagglutinin stem antibody CR9114: Evidence for a narrow evolutionary path towards universal protection

Published in Frontiers in Virology

In collaboration between Leyden Labs and Harvard University, Maastricht University, and the Ragon Institute

October 30, 2022

Exploring the role of antiviral nasal sprays in the control of emerging respiratory infections in the community

Published in Infectious Diseases and Therapy

In collaboration between Leyden Labs and Imperial College London, Harvard University, and the Ragon Institute

September 12, 2021

The molecular mechanism of RIG-I activation and signaling

Published in Immunological Reviews 

June 17, 2021

A stem-loop RNA RIG-I agonist confers prophylactic and therapeutic protection against acute and chronic SARS-CoV-2 infection in mice

Published in Journal of Experimental Medicine 

LL-White

OUR APPROACH  |  OUR PUBLICATIONS  |  ABOUT US   |  NEWS  |  CAREERS  

Contact

Media inquiries

Stay updated

Leyden Laboratories B.V.

Leiden Laboratory
Emmy Noetherweg 2
2333 BK  Leiden
The Netherlands


Leyden Labs Asia Pte. Ltd.

79 Science Park Drive
#04-05, Cintech IV
Singapore 118264


© Leyden Labs, 2026  |  Privacy Statement  |  Design by Ape to Zebra

Back to top Arrow